Your browser is no longer supported. Please, upgrade your browser.
BMRN BioMarin Pharmaceutical Inc. monthly Stock Chart
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E- EPS (ttm)-3.85 Insider Own0.40% Shs Outstand172.75M Perf Week3.56%
Market Cap16.27B Forward P/E- EPS next Y-0.36 Insider Trans-47.01% Shs Float172.19M Perf Month7.81%
Income-630.20M PEG- EPS next Q-0.29 Inst Own100.00% Short Float4.35% Perf Quarter11.68%
Sales1.12B P/S14.57 EPS this Y-253.70% Inst Trans-0.13% Short Ratio6.96 Perf Half Y14.47%
Book/sh16.08 P/B5.86 EPS next Y62.10% ROA-17.20% Target Price111.20 Perf Year4.40%
Cash/sh4.57 P/C20.61 EPS next 5Y25.00% ROE-26.20% 52W Range73.45 - 102.49 Perf YTD13.70%
Dividend- P/FCF- EPS past 5Y-51.20% ROI-17.50% 52W High-8.10% Beta1.66
Dividend %- Quick Ratio2.40 Sales past 5Y20.40% Gross Margin81.20% 52W Low28.24% ATR2.20
Employees2293 Current Ratio3.20 Sales Q/Q31.70% Oper. Margin-71.90% RSI (14)66.71 Volatility2.94% 2.19%
OptionableYes Debt/Eq0.25 EPS Q/Q-207.50% Profit Margin-56.40% Rel Volume1.27 Prev Close93.52
ShortableYes LT Debt/Eq0.24 EarningsMay 04 AMC Payout- Avg Volume1.08M Price94.19
Recom2.00 SMA206.04% SMA504.73% SMA2004.87% Volume1,365,638 Change0.72%
Mar-30-17Initiated UBS Neutral $92
Mar-02-17Initiated Instinet Neutral $93
Feb-07-17Initiated Morgan Stanley Overweight $110
Jan-23-17Resumed Credit Suisse Outperform
Dec-08-16Initiated Gabelli & Co Buy $109
Nov-07-16Downgrade Piper Jaffray Overweight → Neutral
Nov-03-16Initiated Deutsche Bank Buy $106
Aug-05-16Reiterated Stifel Buy $107 → $113
Aug-05-16Reiterated Piper Jaffray Overweight $107 → $120
Mar-08-16Upgrade Robert W. Baird Neutral → Outperform $110
Mar-03-16Reiterated Stifel Buy $105 → $107
Feb-29-16Reiterated Wedbush Neutral $117 → $105
Feb-26-16Reiterated RBC Capital Mkts Outperform $155 → $125
Feb-16-16Upgrade Stifel Hold → Buy $105
Jan-20-16Initiated Credit Suisse Outperform
Jan-19-16Reiterated Wedbush Neutral $125 → $117
Nov-25-15Reiterated Oppenheimer Perform $119 → $115
Nov-18-15Initiated Goldman Buy
Oct-05-15Reiterated Wedbush Neutral $131 → $137
Oct-02-15Initiated Raymond James Outperform $148
Apr-25-17 04:05PM  BioMarin Pharmaceutical, Inc. Value Analysis (NASDAQ:BMRN) : April 25, 2017 Capital Cube
01:44PM  Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates Benzinga
Apr-24-17 08:43AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : April 24, 2017 Capital Cube +5.71%
12:01AM  Biomarin Rare Disease Drug Picks Up European Endorsement Ahead of FDA Action TheStreet.com
Apr-21-17 01:29PM  BioMarin Receives Positive CHMP Opinion in Europe for Brineura (cerliponase alfa) for First Treatment of CLN2 Disease, a Form of Batten Disease and Ultra-Rare and Fatal Brain Disorder in Children PR Newswire
Apr-20-17 04:53PM  BioMarin to Host First Quarter 2017 Financial Results Conference Call and Webcast on Thursday, May 4 at 4:30pm ET PR Newswire
Apr-19-17 07:57AM  Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed Zacks
Apr-17-17 09:20AM  5 Drug Stocks That Could Be Big Winners this Earnings Season Zacks
Apr-14-17 08:05AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : April 14, 2017 Capital Cube
Apr-13-17 04:18PM  The Hot Stock: Alexion Pharmaceuticals Climbs 3.3% Barrons.com
08:30AM  BioMarin Announces Kuvan® (sapropterin dihydrochloride) Patent Challenge Settlement PR Newswire
Apr-12-17 04:42PM  Sarepta Therapeutics Stock History: A Biotech Roller-Coaster Ride Motley Fool
Apr-06-17 08:24AM  3 Stocks We'd Buy and Hold for the Next 20 Years Motley Fool
05:00AM  Just How Much Is a Medical Miracle Worth? Bloomberg
Apr-03-17 07:41AM  4 FDA Decisions to Watch Out for in Apr 2017 Zacks
Apr-02-17 11:41AM  4 Drug Stocks With Big News Coming in April Motley Fool
Mar-30-17 09:24AM  Coverage initiated on BioMarin Pharm by UBS
08:13AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : March 30, 2017 Capital Cube
Mar-28-17 07:10AM  Why Is BioMarin (BMRN) Down 2.2% Since the Last Earnings Report? Zacks
Mar-24-17 04:19PM  Sanofi Could Acquire This Biotech, But Is $1 Billion Too Low?
Mar-23-17 09:47AM  Catalyst Pharma (CPRX) Focused on U.S. Approval for Firdapse Zacks
Mar-16-17 12:03PM  Catalyst Pharmaceuticals Inc (CPRX): Heres Whats Next Insider Monkey
Mar-07-17 09:32AM  Catalyst Pharma (CPRX): What???s in Store in Q4 Earnings?
Mar-06-17 09:28AM  Inovio (INO): What's in the Cards this Earnings Season?
08:46AM  Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store? Zacks
Mar-02-17 01:04PM  BIOMARIN PHARMACEUTICAL INC Financials
Mar-01-17 05:42PM  Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?
05:29PM  Biotechs Leap On Trump's Calls For Innovation, Speedy FDA Approval Investor's Business Daily
07:24AM  Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals Zacks
Feb-28-17 11:36AM  BioMarin Pharmaceutical, Inc. :BMRN-US: Earnings Analysis: 2016 By the Numbers : February 28, 2017
Feb-27-17 09:52AM  BioMarin Pharmaceutical, Inc. :BMRN-US: Earnings Analysis: Q4, 2016 By the Numbers : February 27, 2017
08:15AM  Blog Coverage Cempra Announced Positive Results from the Phase-III Study for the Treatment of Acute Bacterial Skin and Skin Structure Infections Accesswire
06:12AM  BIOMARIN PHARMACEUTICAL INC Files SEC form 10-K, Annual Report
Feb-25-17 11:42AM  BioMarin Pharmaceutical Inc. Logs a Combined Blockbuster at Motley Fool
Feb-24-17 04:18PM  BioMarin 'Attractive' M&A Target Despite Growing Losses: RBC
09:41AM  BioMarin (BMRN) Q4 Loss Narrower than Expected; Sales Beat
03:52AM  Edited Transcript of BMRN earnings conference call or presentation 23-Feb-17 9:30pm GMT
Feb-23-17 04:32PM  BioMarin reports 4Q loss
04:17PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
04:01PM  BioMarin Announces Fourth Quarter and Full Year 2016 Financial Results PR Newswire
07:07AM  Q4 2016 Biomarin Pharmaceutical Inc Earnings Release - Time Not Supplied
Feb-22-17 03:53PM  3 Biotech Stocks You May Be Overlooking at Motley Fool
08:29AM  Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More
06:43AM  Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising
Feb-21-17 02:07PM  JANA Partners Made Massive New Pharma Investments in Q4 at Investopedia
08:15AM  Blog Coverage Celgene's Multiple Sclerosis Drug Reported Positive Phase-III Results Accesswire
Feb-20-17 09:57AM  Better Buy: Alnylam Pharmaceuticals, Inc. vs. BioMarin Pharmaceutical Inc. at Motley Fool
Feb-17-17 08:09AM  BioMarin (BMRN) Q4 Earnings: Will it Post a Beat Again?
Feb-15-17 08:30AM  BioMarin Announces 11 Presentations at 13th Annual WORLDSymposium 2017 PR Newswire
Feb-10-17 09:29AM  Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?
09:28AM  Perrigo Company (PRGO) Q4 Earnings: Disappointment in Store?
Feb-08-17 10:17AM  Gilead Sciences & Bristol Myers: Two Wrongs Make a Right? at Barrons.com
08:30AM  BioMarin to Attend Three Investor Conferences in 1Q17 PR Newswire
Feb-07-17 02:39PM  Your Guide To 2017's Emerging Pharmaceuticals Catalysts
01:24PM  BioMarin sues to stop generic version of its $90K-a-year drug at bizjournals.com
08:30AM  BioMarin to Host Fourth Quarter and Full Year 2016 Financial Results Conference Call and Webcast on Thursday, February 23 at 4:30pm ET PR Newswire
Feb-02-17 10:14AM  BioMarin's Hemophilia Candidate Included in PRIME Initiative
Feb-01-17 04:15PM  BioMarin Receives Access to Priority Medicines (PRIME) Regulatory Support from EMA for BMN 270 Gene Therapy in Hemophilia A PR Newswire
Jan-31-17 10:15AM  4 Top Biotech Stocks With Big Upcoming Catalysts
Jan-30-17 07:24AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : January 30, 2017
Jan-26-17 10:04AM  Is BioMarin (BMRN) Well Poised for Growth in 2017?
Jan-23-17 03:21PM  Were in the year of the biotech buyout, and here are five prime targets at MarketWatch
Jan-19-17 08:40AM  Baird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential
Jan-18-17 09:53AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : January 18, 2017
Jan-10-17 10:33AM  Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears
09:39AM  Top Stocks to Buy Now That the 21st Century Cures Act Has Passed at Motley Fool
Jan-09-17 08:38AM  BioMarin CEO: Positive results for hemophilia treatment
Jan-08-17 09:19PM  BioMarin Pharma cites positive results for hemophilia treatment
07:45PM  BioMarin to Provide Update to Proof-of-Concept Data for BMN 270 Gene Therapy in Hemophilia A at 35th Annual J.P. Morgan Healthcare Conference PR Newswire
Jan-06-17 04:22PM  Could Sanofi Acquire BioMarin In Wake Of Amgen LDL Brouhaha?
10:55AM  Biotech Investing: 3 Bold Predictions for 2017 at Motley Fool
Jan-05-17 08:15AM  Blog Coverage Affimed Join Hands with MD Anderson Cancer Center for Clinical Immuno-Oncology Development Collaboration Accesswire
Jan-04-17 09:30AM  The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen
08:09AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : January 4, 2017
Jan-03-17 08:32AM  3 Overlooked Drug Stocks to Watch Out for in 2017
08:00AM  BioMarin to Present at 35th Annual J.P. Morgan Healthcare Conference in San Francisco PR Newswire
Dec-29-16 10:11AM  BioMarin (BMRN) Raised to Buy: Should You Add the Stock?
Dec-27-16 03:07PM  3 Precision Medicine Stocks to Buy in January at Motley Fool
02:45PM  Time for biotech to boom ... or bust?
Dec-22-16 08:25AM  RBC Likes Large Cap Biotech Leaders for 2017 at 24/7 Wall St.
Dec-21-16 09:35AM  BioMarin Pharmaceutical, Inc. Value Analysis (NASDAQ:BMRN) : December 21, 2016
Dec-20-16 07:40AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : December 20, 2016
Dec-19-16 04:16PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Pr
Dec-15-16 11:02AM  3 Growth Stocks You Should Avoid in 2017 at Motley Fool
Dec-14-16 02:13PM  Will Insurers Pay For Sarepta's DMD Drug? at Barrons.com
Dec-12-16 08:29AM  BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia GlobeNewswire
Dec-09-16 04:16PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
Dec-08-16 03:06PM  [$$] Would Gilead Buy BioMarin? at Barrons.com
Dec-07-16 07:33AM  Do Hedge Funds Love Agilent Technologies Inc (A)? at Insider Monkey
Dec-06-16 10:38AM  Hedge Funds Are Buying BioMarin Pharmaceutical Inc. (BMRN) at Insider Monkey
Dec-04-16 01:04PM  7 of the Most Shocking Biotech Pipeline Blowups of 2016 at Motley Fool
Dec-02-16 04:17PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fina
Nov-29-16 11:58AM  BioMarin Surging Beneath the Surface
Nov-23-16 07:15PM  Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $12.1 million of Shares
10:29AM  5 Biotech Stocks George Soros Is Buying at Motley Fool
Nov-22-16 12:11PM  ETFs with exposure to BioMarin Pharmaceutical, Inc. : November 22, 2016
Nov-21-16 07:20AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : November 21, 2016
Nov-17-16 09:28AM  10 biotech companies ripe for a buyout, courtesy of Donald Trump at MarketWatch
Nov-16-16 08:48AM  Merck KGaA's (MKGAF) Q3 Earnings and Sales Increase Y/Y
Nov-15-16 04:18PM  Soros 13F Points to More Than Just Emerging Markets at Investopedia
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease; pegvaliase, an enzyme substitution therapy for the treatment of PKU; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB. The company serves specialty pharmacies and end-users, such as hospitals and foreign government agencies; and distributors and pharmaceutical wholesalers. BioMarin Pharmaceutical Inc. has a collaboration agreement with Genzyme Corporation. The company was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIENAIME JEAN JACQUESChief Executive OfficerApr 04Option Exercise14.393,00043,170238,194Apr 06 05:28 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 29Sale89.153,890346,79451,532Mar 31 05:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 16Option Exercise71.335,000356,650195,674Mar 17 06:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 16Sale91.965,000459,800190,674Mar 17 06:27 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 16Sale91.961,989182,90814,471Mar 17 06:30 PM
Davis George EricEVP, General CounselMar 16Sale91.962,238205,80673,729Mar 17 06:31 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 15Option Exercise17.335,00086,650211,364Mar 17 06:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 15Sale91.425,000457,100206,364Mar 17 06:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 13Option Exercise17.335,00086,650211,364Mar 15 07:16 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 13Sale92.685,000463,400206,364Mar 15 07:16 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 10Option Exercise17.335,00086,650211,364Mar 13 07:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 10Sale91.095,000455,450206,364Mar 13 07:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 09Option Exercise17.336,000103,980212,364Mar 13 07:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 09Sale90.186,000541,080206,364Mar 13 07:59 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 07Sale90.565,000452,80046,510Mar 08 07:31 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 06Sale93.322,303214,91620,761Mar 08 07:28 PM
Davis George EricEVP, General CounselMar 06Sale93.321,498139,79378,962Mar 08 07:24 PM
LAWLIS V BRYANDirectorMar 01Option Exercise17.337,500129,97521,360Mar 02 06:14 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 01Sale94.505,000472,50025,347Mar 02 06:20 PM
LAWLIS V BRYANDirectorMar 01Sale95.007,500712,50013,860Mar 02 06:14 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerFeb 28Option Exercise63.1030,0001,893,00060,347Mar 02 06:20 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerFeb 28Sale94.0030,0002,820,00030,347Mar 02 06:20 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 26Option Exercise17.335,00086,650175,682Jan 27 05:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 26Sale84.005,000420,000170,682Jan 27 05:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 25Option Exercise17.335,00086,650175,682Jan 27 05:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 25Sale84.445,000422,200170,682Jan 27 05:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 11Option Exercise17.334,00069,320174,682Jan 12 06:48 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 11Sale89.844,000359,360170,682Jan 12 06:48 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 10Option Exercise17.334,00069,320174,682Jan 12 06:48 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 10Sale91.314,000365,240170,682Jan 12 06:48 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 09Option Exercise17.334,00069,320174,682Jan 10 04:53 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 09Sale89.794,000359,160170,682Jan 10 04:53 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerJan 09Sale90.005,000450,00018,100Jan 10 04:50 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 06Option Exercise17.334,00069,320174,682Jan 10 04:53 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 06Sale87.194,000348,760170,682Jan 10 04:53 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 30Option Exercise17.334,00069,320174,682Jan 03 05:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 30Sale83.354,000333,400170,682Jan 03 05:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 29Option Exercise17.334,00069,320174,682Jan 03 05:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 29Sale83.844,000335,360170,682Jan 03 05:46 PM
FUCHS HENRY JPresident, Worldwide R&DNov 25Option Exercise26.4915,000397,350128,878Nov 29 08:34 PM
FUCHS HENRY JPresident, Worldwide R&DNov 25Sale87.4015,0001,310,988113,878Nov 29 08:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 22Option Exercise26.4969,7431,847,492240,425Nov 23 04:42 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 22Sale85.6969,7435,976,515170,682Nov 23 04:42 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 21Option Exercise26.4969,7441,847,519240,426Nov 23 04:42 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 21Sale87.5669,7446,106,478170,682Nov 23 04:42 PM
Davis George EricEVP, General CounselNov 18Option Exercise38.595,000192,95075,798Nov 22 07:13 PM
Davis George EricEVP, General CounselNov 18Sale90.425,000452,10070,798Nov 22 07:13 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 16Option Exercise17.5441,670730,892365,038Nov 18 05:37 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 16Sale90.9741,6703,790,795323,368Nov 18 05:37 PM
LAWLIS V BRYANDirectorNov 09Option Exercise17.337,500129,97521,360Nov 14 01:59 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerNov 09Sale90.6120,0001,812,20623,100Nov 14 02:02 PM
LAWLIS V BRYANDirectorNov 09Sale95.007,500712,50013,860Nov 14 01:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 08Option Exercise21.5170,0001,505,700393,368Nov 09 08:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 08Sale82.8370,0005,797,806323,368Nov 09 08:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 07Option Exercise21.5170,0001,505,700393,368Nov 09 08:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 07Sale82.5270,0005,776,435323,368Nov 09 08:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 28Option Exercise14.3960,000863,400383,368Oct 31 07:33 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 28Sale81.2760,0004,875,990323,368Oct 31 07:33 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 27Option Exercise14.3960,000863,400383,368Oct 31 07:33 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 27Sale81.3460,0004,880,448323,368Oct 31 07:33 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 17Option Exercise17.5441,666730,822365,034Oct 19 04:41 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 17Sale84.3941,6663,516,227323,368Oct 19 04:41 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 14Option Exercise17.8611,000196,460334,368Oct 17 07:16 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 14Sale86.8911,000955,814323,368Oct 17 07:16 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 13Option Exercise38.5953,1252,050,094376,493Oct 17 07:16 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 13Sale86.9853,1254,620,563323,368Oct 17 07:16 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 30Option Exercise38.5953,1252,050,094431,709Oct 04 03:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 30Sale92.0253,1254,888,780378,584Oct 04 03:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 29Option Exercise38.5953,1252,050,094431,709Oct 03 06:37 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 29Sale93.6553,1254,974,901378,584Oct 03 06:37 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerSep 27Sale95.6118,4671,765,64841,342Sep 29 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 16Option Exercise29.3494,7912,780,915431,709Sep 19 06:41 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 16Sale95.5694,7919,058,600378,584Sep 19 06:41 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 15Option Exercise17.3342,577737,859421,161Sep 19 06:41 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 15Sale94.8542,5774,038,360378,584Sep 19 06:41 PM
FUCHS HENRY JEVP, Chief Medical OfficerAug 26Option Exercise26.4915,000397,350128,878Aug 30 09:07 PM
FUCHS HENRY JEVP, Chief Medical OfficerAug 26Sale95.0615,0001,425,924113,878Aug 30 09:07 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 16Option Exercise17.5441,666730,822420,250Aug 17 04:37 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 16Sale91.4941,6663,811,868378,584Aug 17 04:37 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerAug 01Sale99.334,000397,32042,944Aug 03 10:19 AM
Davis George EricEVP, General CounselAug 01Sale100.002,167216,70071,158Aug 03 10:13 AM
Mueller BrianVP, Corporate ControllerAug 01Sale100.0028728,70014,260Aug 03 10:12 AM
LAWLIS V BRYANDirectorJul 27Option Exercise17.331,10019,06314,960Jul 28 07:02 PM
LAWLIS V BRYANDirectorJul 27Sale95.391,100104,92713,860Jul 28 07:02 PM
LAWLIS V BRYANDirectorJul 22Option Exercise17.336,400110,91220,260Jul 26 06:57 PM
LAWLIS V BRYANDirectorJul 22Sale95.016,400608,06413,860Jul 26 06:57 PM
BIENAIME JEAN JACQUESChief Executive OfficerJul 18Option Exercise17.5441,666730,822420,250Jul 20 07:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerJul 18Sale92.7241,6663,863,272378,584Jul 20 07:51 PM
Davis George EricEVP, General CounselJul 14Option Exercise38.592,656102,49573,325Jul 18 06:02 PM
Davis George EricEVP, General CounselJul 07Sale90.002,167195,03070,669Jul 11 04:45 PM
LAWLIS V BRYANDirectorJun 20Sale82.7755045,52413,860Jun 21 04:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 16Option Exercise17.5441,666730,822420,250Jun 20 08:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 16Sale80.5541,6663,356,196378,584Jun 20 08:23 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerJun 06Sale89.141,649146,99246,944Jun 08 08:39 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMay 31Option Exercise39.0616,896659,95871,235Jun 02 06:21 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMay 31Sale89.8820,8411,873,12650,394Jun 02 06:21 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 26Option Exercise26.4915,000397,350130,914May 31 06:52 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 26Sale87.8115,0001,317,100115,914May 31 06:52 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMay 23Sale87.073,769328,18458,644May 25 02:57 PM
BAFFI ROBERTEVP, Technical OperationsMay 18Sale87.055,000435,249130,386May 19 03:53 PM